ArticleEuropean journal of nuclear medicine and molecular imaging2022
Hetero-bivalent agents targeting FAP and PSMA.
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- FAPI Dimerization for Theranostic Applications: Molecular Design, Preclinical Validation, and Clinical Translation.Chemical & biomedical imaging · 2026Review
- Advancing the understanding of tumor microenvironment through medical imaging based on bibliometric analysis.Translational cancer research · 2026Article
- Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective.European journal of nuclear medicine and molecular imaging · 2026Review
- Preclinical evaluation and first-in-human study ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.Acta pharmaceutica Sinica. B · 2025Review
- Synthesis and Preclinical Evaluation of Dual-Targeted Molecular Tracer for Positron Emission Tomography Imaging of Programmed Cell Death Ligand‑1 and Integrin αACS pharmacology & translational science · 2025Article
- Cancer-Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets.MedComm · 2025Review
- The role of cancer-associated fibroblasts in the tumour microenvironment of urinary system.Clinical and translational medicine · 2025Review
- Design, preclinical evaluation, and first-in-human PET study of [European journal of nuclear medicine and molecular imaging · 2025Article
- Development and evaluation of albumin binder-conjugated heterodimeric radiopharmaceuticals targeting integrin αEuropean journal of nuclear medicine and molecular imaging · 2024Article
- Enhanced Detection of Early Pulmonary Fibrosis Disease UsingMolecular pharmaceutics · 2024Article
- Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.Advanced healthcare materials · 2024Article
- Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin αEuropean journal of nuclear medicine and molecular imaging · 2024Article
- Design, Preclinical Evaluation, and Clinical Translation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Synthesis and Preclinical Evaluation of Two NovelMolecules (Basel, Switzerland) · 2024Article
- Carrier systems of radiopharmaceuticals and the application in cancer therapy.Cell death discovery · 2024Review
- Prostate-specific membrane antigen-targeted surgery in prostate cancer: Accurate identification, real-time diagnosis, and precise resection.Theranostics · 2024Review
- Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma.Frontiers in oncology · 2024Article
- Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future.Cancers · 2023Review
- Theranostics in targeting fibroblast activation protein bearing cells: Progress and challenges.Life sciences · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
purposeWe developed a theranostic radiopharmaceutical that engages two key cell surface proteases, fibroblast activation protein alpha (FAP) and prostate-specific membrane antigen (PSMA), each frequently overexpressed within the tumor microenvironment (TME). The latter is also expressed in most prostate tumor epithelium. To engage a broader spectrum of cancers for imaging and therapy, we conjugated small-molecule FAP and PSMA-targeting moieties using an optimized linker to provide
methodsWe synthesized FP-L1 and FP-L2 using two linker constructs attaching the FAP and PSMA-binding pharmacophores. We determined in vitro inhibition constants (K
results
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.